ReviewEuropean journal of haematology2026
Surgical Management of Solid Tumors With Hematologic Manifestations: A Mechanism-Based Clinical Review.
Review in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solid tumors can be associated with a variety of hematologic manifestations, including paraneoplastic syndromes, coagulopathy, and electrolyte derangements. Evaluation and management require a multidisciplinary approach and a clear understanding of the role and timing of surgical resection, as this can provide definitive treatment. This review summarizes current literature and offers a practical approach to stabilization and surgical-focused management of solid tumors presenting with hematologic manifestations. The scope focuses on hematologic or metabolic paraneoplastic presentations with direct relevance to surgical timing and perioperative care; endocrine hormone excess syndromes (e.g., ectopic ACTH, SIADH) are excluded. For mechanism-linked hematologic or metabolic manifestations, early surgical consultation is recommended. Bridge therapies enable safe anesthesia and resection, while durable correction generally requires tumor control. A standardized, age-focused perioperative approach is integral for optimal patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.